AI Insight
A study presented at the American Diabetes Association annual meeting found that continuous glucose monitoring (CGM) significantly reduces glycated hemoglobin (HbA1c) levels in adults with type 2 diabetes who are not using insulin therapy. The research demonstrates that CGM technology, which provides real-time glucose readings throughout the day, can benefit a broader population of type 2 diabetes patients beyond those currently on insulin treatment. The reduction in HbA1c indicates improved long-term blood sugar control in this patient group.
Why it matters
This finding could expand the use of CGM devices to millions of type 2 diabetes patients not on insulin, potentially improving their disease management and reducing complications. The results suggest that insurance coverage and clinical guidelines for CGM should be reconsidered to include non-insulin-using patients with type 2 diabetes.
Understand the Science
For adults with type 2 diabetes (T2D) not on insulin therapy (NIT), continuous glucose monitoring (CGM) is associated with a substantial reduction in glycated hemoglobin (HbA1c), according to a study presented at the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.
Source: ADA: Continuous glucose monitoring lowers HbA1c in adults with type 2 diabetes not on insulin